Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sierra Oncology

Recap: Sierra Oncology Q1 Earnings

Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Analyst Ratings for Sierra Oncology

Analyst Ratings for Sierra Oncology

Sierra Oncology (NASDAQ:SRRA) has observed the following analyst ratings within the last quarter:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Wednesday's Intraday Session

Sierra Oncology Stock Is Soaring: Here's Why

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a

GSK buys US-based cancer specialist Sierra Oncology for $1.9 billion

Deal is in step with GSK’s strategy of building a strong portfolio of new specialty medicines and vaccines

Evening Standard

Biotech Feeding Spree As GSK, Halozyme Announce Nearly $3 Billion In Deals

GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Sierra Oncology Raises $135M Via Equity To Fund Lead Program Development

Sierra Oncology Raises $135M Via Equity To Fund Lead Program Development

Sierra Oncology Inc (NASDAQ: SRRA) has priced its underwritten public offering of 4.07 million shares at $27 per share and the pre-funded warrants at $26.999 per pre-funded warrant.

Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way

Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way

Sierra Oncology reported a late-stage win Tuesday for a bone cancer drug it acquired at a discount — and the biotech stock catapulted.

Investors Business Daily

Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development

Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development

Sierra Oncology Inc (NASDAQ: SRRA) has

Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal

Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal

Sierra Oncology Inc (NASDAQ: SRRA)

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

1

Organisations

B of A Securities

SolarEdge Technologies

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play